Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00313300 · ClinicalTrials.gov registry record · Phase 2
Safety Study of Apixaban in Recent Acute Coronary Syndrome
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,741
- Enrollment target
NCT00313300: Completed Phase 2 study, sponsored by Bristol-Myers Squibb.
NCT00313300 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 1,741 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (1209% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00313300, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,741 participants
- Enrollment target
Study Summary
The purpose of this clinical research study is to determine whether apixaban will be safe in people who have recently had unstable angina or a heart attack.
Primary Outcome
Bleeding was assessed using the International Society on Thrombosis and Hemostasis (ISTH) guidelines. Events were adjudicated by the Clinical Events Committee (CEC). Event rate was number of participants with events divided by the number of participants treated, measured as a percentage (%). The primary outcome is based on data for the placebo and 2 apixaban low-dose groups (2.5 mg BID and 10 mg QD) combined across Phase A and Phase B. The analyses of Phase B data across all doses of apixaban ar
Interventions
- DRUG Placebo
- DRUG Apixaban
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,741 participants |
| Start Date | 2006-05 |
| Est. Completion | 2008-05 |
| Phase | Phase 2 |
What the finished NCT00313300 record still lists
NCT00313300 is an interventional study that assigns participants to a tested intervention. Its 1,741 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (1209% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00313300 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00313300 about?
NCT00313300 is a clinical study titled "Safety Study of Apixaban in Recent Acute Coronary Syndrome". The purpose of this clinical research study is to determine whether apixaban will be safe in people who have recently had unstable angina or a heart attack.
What is the current status of trial NCT00313300?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,741 participants. The study started on 2006-05. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00313300?
The interventions under investigation include: Placebo (DRUG), Apixaban (DRUG).
Who is sponsoring clinical trial NCT00313300?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00313300's enrollment target sits among peer trials
1,741 11th of 2000 higher than 1,990 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04712656 · 1,739 participants
Effects of CPAP Therapy on Blood Pressure and Heart Rate Variability in Obstructive Sleep Apnea
- NCT05934487 · 1,750 participants · NA
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
- NCT06954337 · 1,750 participants · NA
MATCH-UP: MAking Telehealth-Delivery of Cancer Care at Home Effective and Safe-Upscaled: A Pragmatic Cluster Randomized Trial
- NCT07183527 · 1,750 participants · NA
Hybrid Type I Effectiveness-implementation Cluster Randomized Controlled Trial of CARES
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia